Celltrion (Chairman Seo Jeong-jin) announced on the 15th that it has received approval from the European Commission (EC) to sell the biosimilar’CT-P17′ for the autoimmune disease treatment Humira (adalimumab).
According to the company,’Uplasma’ is the world’s first high-concentration formulation as an adalimumab-based biosimilar, and while the existing Humira biosimilar products were developed at a low concentration, which is an old type, Uplasma is a new type. It is a (New Type) high-concentration formulation, which cuts the drug dose in half and eliminates citrate (citrate) that can cause pain, thus securing differentiated marketability and high marketability at the same time.
U Plaima plans to enter the market early through the process of listing drug prices by country in Europe as soon as possible through Celltrion Healthcare, which is in charge of global marketing and distribution.
In particular, since the new type of Humira biosimilar will be introduced for the first time in Europe, Celltrion Healthcare announced that it will maximize its market share before launching competitive products by actively utilizing the benefits of’First Mover’.
An official from Celltrion said, “Celltrion has focused on development as a high-concentration type with higher marketability. With this EC approval, UPlaima’s differentiated competitiveness has been recognized, and we are able to introduce the world’s first new type Humira biosimilar in Europe.” “We plan to provide the benefits of high-quality biopharmaceuticals reasonably by supplying them to European medical staff and patients who have been waiting for a new type of Humira biosimilar as soon as possible.”
Copyright © Pax Economic TV Unauthorized reproduction and redistribution prohibited